سعر بيوبريكس 2.5 مجم 30 قرص مغلف 2024

Film-coated tablets containing olanzapine 2.5 mg.

• Treatment of schizophrenia; maintenance of clinical improvement during continuation therapy in respondersPopulation: Adultselectronic medicines compendium (emc), MHRA
• Treatment of moderate to severe manic episode; prevention of recurrence in bipolar disorder in patients whose manic episode has responded to olanzapinePopulation: Adultselectronic medicines compendium (emc), MHRA

• Very common/common: somnolence, weight gain, elevated prolactin/cholesterol/glucose/triglycerides, increased appetite, dizziness, akathisia, parkinsonism, orthostatic hypotension, anticholinergic effects, transient ALT/AST elevations, fatigue.International label, equivalent formulation · electronic medicines compendium (emc), MHRA

• Hypersensitivity to the active substance or to any of the excipients; patients with known risk of narrow-angle glaucoma.International label, equivalent formulation · electronic medicines compendium (emc), MHRA

• Not recommended in dementia-related psychosis/behavioural disturbances (increased mortality and cerebrovascular events in elderly). Not recommended for dopamine-agonist psychosis in Parkinson's disease.International label, equivalent formulation · electronic medicines compendium (emc), MHRA
• Monitor for hyperglycaemia/diabetes, weight gain and lipid alterations; risk of neuroleptic malignant syndrome; caution with QTc-prolonging drugs; address VTE risk factors; not for use below 18 years.International label, equivalent formulation · electronic medicines compendium (emc), MHRA
• US labeling for olanzapine film-coated tablets: boxed warning for increased mortality in elderly patients with dementia-related psychosis; not approved for dementia-related psychosis.International label, same formulation · DailyMed

• CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin)MajorFluvoxamine significantly inhibits olanzapine metabolism; consider lower starting dose of olanzapine and dose reduction if a CYP1A2 inhibitor is started.electronic medicines compendium (emc), MHRA
• CYP1A2 inducers (smoking, carbamazepine)ModerateSmoking and carbamazepine may induce olanzapine metabolism and reduce concentrations; clinical monitoring and possible dose increase.electronic medicines compendium (emc), MHRA
• Alcohol / CNS depressantsModerateCaution with alcohol or medicinal products that cause CNS depression.electronic medicines compendium (emc), MHRA

• No adequate well-controlled studies in pregnant women; use in pregnancy only if potential benefit justifies potential risk to the foetus. Neonates exposed during the third trimester are at risk of extrapyramidal and/or withdrawal symptoms.International label, equivalent formulation · electronic medicines compendium (emc), MHRA
• Olanzapine is excreted in breast milk; patients should be advised not to breast-feed an infant if they are taking olanzapine.International label, equivalent formulation · electronic medicines compendium (emc), MHRA

English text not available for this section.